Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 106, Issue 3, 2004, Pages 230-232

  Mahovic, Darija ^a   Petravic, Damir ^a   Petelin, Zeljka ^a   Zurak, Niko ^c   Horvat, Gordana ^b   Hajnsek, Sanja ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c NONE

Author keywords

Apoptosis; ELISA; Multiple sclerosis; sFas APO 1

Indexed keywords

FAS ANTIGEN;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MULTIPLE SCLEROSIS; PATHOGENESIS; RECURRENCE RISK; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, CD95; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS;

EID: 2642559404     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2004.02.020     Document Type: Article

References (17)

1. Fukunaga R., Brannan C., Copeland N., Jenkins N., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediated apoptosis. Nature. 356:1992;314-317
2. Zurak N. Programmed cell death, apoptosis and nervous system. Neurol. Croat. 46:1997;3-18
3. Dhein J., Walczak H., Baumler C., Debatin K., Krammer P. Autocrine T-cell suicide mediated by Apo-1/(Fas/CD95). Nature. 373:1995;438-441
4. Nagata S., Suda T. Fas and Fas ligand: 1pr and gld mutations. Immunol. Today. 16:1995;39-43
5. Abbas A. Die and let live: eliminating dangerous lymphocytes. Cell. 84:1996;655-657
6. Papoff G., Cascino I., Eramo A., Starace G., Lynch D., Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol. 156:1996;4622-4630
7. Zipp F., Martin R., Lichtenfels R., Roth W., Dichgans J., Krammer P., et al. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J. Immunol. 159:1997;2108-2115
8. Prat A., Biernacki K., Lavoie J., Poirier J., Inf B., Duquette P., et al. Migration of multiple sclerosis lymphocytes through brain endothelium. Arch. Neurol. 59:2002;391-397
9. Poser C., Paty D., Scheinberg L., McDonald W., Davis F., Ebers G., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-234
10. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452
11. Bansil S., Holtz C., Cook S., Rohowsky-Kochan C. Serum sAPO 1/Fas levels in multiple sclerosis. Acta Neurol. Scand. 95:1997;208-210
12. Ciusani E., Frigeroi S., Gelati M., Corsoini E., Dufour A., Nespolo A., et al. Soluble Fas (APO 1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 82:1998;5-12
13. Zipp F., Weller M., Calabresi C., Frank J., Bash C., Dichgans J., et al. Increased serum levels of soluble CD95 (APO-1, Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. 43:1998;116-120
14. Bilinska M., Frydecka I., Podemski R., Gruszka E. Fas expression on T cells and sFas in relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 107:2003;387-393
15. Inoue A., Koh C., Sakai T., Yamazaki M., Yanagisawa N., Usuku K., et al. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J. Neuroimmunol. 75:1997;141-146
16. Cheng J., Zhou T., Liu C., Shapiro J., Brauer M., Kiefer M., et al. Protection from Fas-mediatedapoptosis by a soluble form of the Fas molecule. Science. 265:1994;528-530
17. Cascino I., Fiucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:1995;2706-2713